Published Date: 04 Mar 2023
United States: Empagliflozin could be a new treatment option for children and adolescents with type 2 diabetes, with phase 3 clinical trials showing...
Read Full News1.
FDA Approves Monthly Dosing of Rybrevant Faspro for NSCLC
2.
Cancer mortality continuing to decline, says report
3.
Schizophrenia patients are motivated by music therapy.
4.
Infection Burden High With Myeloma T-Cell Therapies
5.
Revolutionary Cancer Tx Could Transform Autoimmune Disease
1.
The Benefits and Risks of Thrombolytics: A Comprehensive Guide
2.
Strategic Developments in Hematology and Quality Improvement
3.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
4.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
5.
Neoadjuvant Abraxane Chemotherapy Combined with Neutrophil Cytopharmaceuticals and Radiotherapy
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
2.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
3.
Navigating the Complexities of Ph Negative ALL - Part VIII
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
5.
Oropharyngeal Cancer in Relation to HPV Status
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation